A.H. Honkoop

753 total citations
20 papers, 577 citations indexed

About

A.H. Honkoop is a scholar working on Oncology, Cancer Research and Hematology. According to data from OpenAlex, A.H. Honkoop has authored 20 papers receiving a total of 577 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 7 papers in Cancer Research and 3 papers in Hematology. Recurrent topics in A.H. Honkoop's work include Cancer Treatment and Pharmacology (10 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (5 papers). A.H. Honkoop is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (5 papers). A.H. Honkoop collaborates with scholars based in Netherlands, United Kingdom and Portugal. A.H. Honkoop's co-authors include Giuseppe Giaccone, Klaas Hoekman, HM Pinedo, S. C. Linn, John Wagstaff, J. van Doorn, Bart Rikhof, Henk Bilo, Winette T.A. van der Graaf and Paul van der Valk and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

A.H. Honkoop

20 papers receiving 560 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A.H. Honkoop Netherlands	10	298	211	135	107	78	20	577
Saverio Danese Italy	16	408 1.4×	199 0.9×	228 1.7×	114 1.1×	99 1.3×	31	880
Matilde Cacciatore Italy	12	293 1.0×	166 0.8×	122 0.9×	161 1.5×	58 0.7×	21	630
Timothy P. Spiro United States	14	289 1.0×	161 0.8×	260 1.9×	132 1.2×	122 1.6×	32	700
Shoshu Mitsuyama Japan	16	337 1.1×	293 1.4×	100 0.7×	130 1.2×	216 2.8×	82	737
Francis Parnis Australia	14	328 1.1×	160 0.8×	186 1.4×	457 4.3×	100 1.3×	60	761
Thierry Nguyen France	15	281 0.9×	95 0.5×	93 0.7×	203 1.9×	62 0.8×	40	613
Antonio De Leo Italy	17	228 0.8×	155 0.7×	191 1.4×	230 2.1×	130 1.7×	101	869
R. Knight United Kingdom	15	367 1.2×	275 1.3×	66 0.5×	134 1.3×	118 1.5×	32	642
David Saavedra-Pérez Spain	9	276 0.9×	142 0.7×	94 0.7×	163 1.5×	51 0.7×	29	580
A. Van Oosterom Belgium	11	268 0.9×	124 0.6×	228 1.7×	209 2.0×	34 0.4×	28	572

Countries citing papers authored by A.H. Honkoop

Since Specialization

Citations

This map shows the geographic impact of A.H. Honkoop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A.H. Honkoop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A.H. Honkoop more than expected).

Fields of papers citing papers by A.H. Honkoop

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A.H. Honkoop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A.H. Honkoop. The network helps show where A.H. Honkoop may publish in the future.

Co-authorship network of co-authors of A.H. Honkoop

This figure shows the co-authorship network connecting the top 25 collaborators of A.H. Honkoop. A scholar is included among the top collaborators of A.H. Honkoop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A.H. Honkoop. A.H. Honkoop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Geurts, Sandra M. E., Loes Kooreman, Astrid C P Swinkels, et al.. (2025). The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial. ESMO Open. 10(2). 104154–104154. 1 indexed citations

Erdkamp, Frans, et al.. (2020). Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer. 1 indexed citations

Erdkamp, Frans, Marta López‐Yurda, Harm van Tinteren, et al.. (2019). Intermittent versus continuous chemotherapy beyond first-line for patients with HER2-negative advanced breast cancer (BOOG 2010-02). Annals of Oncology. 30. iii50–iii51. 1 indexed citations

Bos, Monique E.M.M., Marta López‐Yurda, A.H. Honkoop, et al.. (2017). Efficacy of two times four versus continuous eight cycles of paclitaxel/bevacizumab as first-line chemotherapy in metastatic breast cancer: The Stop&Go study of the Dutch Breast Cancer Research Group (BOOG). Annals of Oncology. 28. v78–v79. 1 indexed citations

Drukker, Caroline A., Gabe S. Sonke, Étienne Brain, et al.. (2014). Risk estimations and treatment decisions in early stage breast cancer: Agreement among oncologists and the impact of the 70-gene signature. European Journal of Cancer. 50(6). 1045–1054. 14 indexed citations

Taal, Walter, Hendrika M. Oosterkamp, Annemiek Walenkamp, et al.. (2014). O10.05 * FINAL ANALYSIS OF THE BELOB TRIAL (A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENT IN RECURRENT GLIOBLASTOMA) AND FIRST RADIOLOGY REVIEW RESULTS. Neuro-Oncology. 16(suppl 2). ii24–ii24. 3 indexed citations

Lam, Siu W., A.H. Honkoop, Agnes Jager, et al.. (2014). Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial. European Journal of Cancer. 50(18). 3077–3088. 25 indexed citations

Rikhof, Bart, et al.. (2007). Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. Endocrine Related Cancer. 14(4). 979–993. 161 indexed citations

Punt, Cornelis J.A., Miriam Koopman, J. Douma, et al.. (2007). Sequential compared to combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC): A Dutch Colorectal Cancer Group (DCCG) phase III study. Journal of Clinical Oncology. 25(18_suppl). 4012–4012. 7 indexed citations

10.

Koopman, Miriam, Ninja Antonini, J. Douma, et al.. (2007). 3015 ORAL Sequential vs. combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC). A Dutch Colorectal Cancer Group (DCCG) phase III study. European Journal of Cancer Supplements. 5(4). 239–240. 1 indexed citations

11.

Koopman, Miriam, Ninja Antonini, J. Douma, et al.. (2006). Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study. Annals of Oncology. 17(10). 1523–1528. 32 indexed citations

12.

Jong, P.C.M. Pasker-de, Robert S. de Jong, A.H. Honkoop, et al.. (2005). Combination chemotherapy with docetaxel and gemcitabine in anthracycline pretreated patients with metastatic breast cancer (MBC). Journal of Clinical Oncology. 23(16_suppl). 728–728. 3 indexed citations

13.

Groeningen, C.J. van, et al.. (2005). Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial. European Journal of Cancer. 41(11). 1560–1569. 36 indexed citations

14.

Smit, Willem M., A.H. Honkoop, S. Špánik, et al.. (2004). A phase I/II dose-escalation trial of EPO906 every 3 weeks in patients with relapsed/refractory ovarian, primary fallopian, or primary peritoneal cancer. Journal of Clinical Oncology. 22(14_suppl). 5102–5102. 2 indexed citations

15.

Honkoop, A.H., S. C. Linn, Giuseppe Giaccone, et al.. (1998). Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. British Journal of Cancer. 77(4). 621–626. 144 indexed citations

16.

Honkoop, A.H., Elsken van der Wall, N Feller, et al.. (1997). Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer. Annals of Oncology. 8(10). 957–962. 15 indexed citations

17.

Honkoop, A.H., et al.. (1996). Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously. British Journal of Cancer. 74(7). 1132–1136. 15 indexed citations

18.

Honkoop, A.H., Klaas Hoekman, John Wagstaff, et al.. (1996). Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients. Annals of Oncology. 7(1). 35–39. 18 indexed citations

19.

Linn, S. C., A.H. Honkoop, Klaas Hoekman, et al.. (1996). p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. British Journal of Cancer. 74(1). 63–68. 91 indexed citations

20.

Honkoop, A.H. & H. M. Pinedo. (1995). HIGH-DOSE CHEMOTHERAPY IN THE TREATMENT OF BREAST-CANCER. International Journal of Oncology. 6(4). 911–8. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact